Study identification

EU PAS number

EUPAS41963

Study ID

46244

Official title and acronym

Registry of Asthma Patients Initiating DUPIXENT® (RAPID)

DARWIN EU® study

No

Study countries

Canada
Denmark
France
Italy
Japan
Puerto Rico
Spain
Sweden
United Kingdom
United States

Study description

The primary objective of the study is to characterize the patients who initiate treatment for asthma with DUPIXENT® in a real-world setting to understand the attributes of treated patients in real life. This includes characterization of: • Patient demographics (eg, gender, age, and race) • Patient baseline characteristics (eg, prior medications and procedures, medical history, asthma history, weight, height) The secondary objectives of the study are: • To characterize real-world use patterns of DUPIXENT® for asthma • To assess the long-term effectiveness of DUPIXENT® in asthma patients in a real-world setting • To assess effectiveness on comorbid type 2 inflammatory conditions in asthma patients treated with DUPIXENT® • To collect long-term safety data on study participants in the real-world setting

Study status

Ongoing
Research institutions and networks

Institutions

Contact details

Study Director Regeneron

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual:

Study start date

Actual:

Data analysis start date

Planned:

Date of final study report

Planned:
Sources of funding
Other
Pharmaceutical company and other private sector 

More details on funding

Regeneron Pharmaceuticals, Inc., Sanofi (Collaborator)
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable